Clinical Trial Update: Diagnostic Accuracy Study for OWL-EVO1 As a Lung Cancer EVOC® Probe (Evolution Phase 2) [Phase 2]

View source ↗

Summary

This update describes a Phase 2 diagnostic accuracy trial evaluating OWL-EVO1 as a lung cancer imaging probe (EVOC) by Owlstone Ltd, which is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• OWL-EVO1

Snippet

Sponsor: Owlstone Ltd | Conditions: Lung Cancer | Phase 2 | Status: RECRUITING